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Random mutagenesis and genetic screens for im-
paired Raf function in Caenorhabditis elegans were
used to identify six loss-of-function alleles of lin-45 raf
that result in a substitution of a single amino acid. The
mutations were classified as weak, intermediate, and
strong based on phenotypic severity. We engineered
these mutations into the homologous residues of verte-
brate Raf-1 and analyzed the mutant proteins for their
underlying biochemical defects. Surprisingly, pheno-
type strength did not correlate with the catalytic activ-
ity of the mutant proteins. Amino acid substitutions Val-
589 and Ser-619 severely compromised Raf kinase
activity, yet these mutants displayed weak phenotypes
in the genetic screen. Interestingly, this is because these
mutant Raf proteins efficiently activate the MAPK (mi-
togen-activated protein kinase) cascade in living cells, a
result that may inform the analysis of knockout mice.
Equally intriguing was the observation that mutant pro-
teins with non-functional Ras-binding domains, and
thereby deficient in Ras-mediated membrane recruit-
ment, displayed only intermediate strength phenotypes.
This confirms that secondary mechanisms exist to cou-
ple Ras to Raf in vivo. The strongest phenotype in the
genetic screens was displayed by a S508N mutation that
again did not correlate with a significant loss of kinase
activity or membrane recruitment by oncogenic Ras in
biochemical assays. Ser-508 lies within the Raf-1 activa-
tion loop, and mutation of this residue in Raf-1 and the
equivalent Ser-615 in B-Raf revealed that this residue
regulates Raf binding to MEK. Further characterization
revealed that in response to activation by epidermal
growth factor, the Raf-S508N mutant protein displayed
both reduced catalytic activity and aberrant activation
kinetics: characteristics that may explain the C. elegans
phenotype.
The importance of the Ras signaling pathway in the regula-
tion of cellular proliferation, differentiation, and survival has
been well established using a variety of biochemical and ge-
netic systems. One of the main Ras effectors is Raf, a serine/
threonine kinase that is evolutionarily conserved in higher
eukaryotes. Raf is a critical part of a signaling cascade that
connects cell-surface receptors with regulatory events within
the cell (1–4). Activated Raf proteins phosphorylate MEKs1 on
two serine residues, which in turn phosphorylate and activate
ERKs (5–7).
Raf is localized to the cytoplasm as an inactive multi-protein
complex. The activation of eukaryotic endogenous Raf mole-
cules is dependent on relieving the interaction between the
N-terminal regulatory and C-terminal kinase domain of the
Raf molecule (8, 9). The initial event in Raf activation is the
recruitment of Raf from the cytosol to the plasma membrane
through a high affinity interaction between the switch 1 region
of activated Ras-GTP and the N-terminal minimal Ras-binding
domain of Raf (Raf RBD) (10–14). This step is critical for Raf
activation as point mutations within Ras or Raf that disrupt
this interaction block Raf activation (15, 16). However, the
interaction between Ras and Raf alone is not sufficient for full
Raf activation, because Ras-GTP cannot activate Raf unless
Ras-GTP is membrane bound (12). Full Raf activation involves
interaction of the Raf cysteine-rich domain (Raf CRD) with Ras
and membrane phospholipids, dephosphorylation of specific
Raf serine residues, and a complex series of phosphorylation
events at serine, tyrosine, and threonine residues.
Several proteins bind to Raf and regulate its activity. The
chaperone proteins Hsp90 and Cdc37 bind to and stabilize
mammalian Raf proteins, holding them in a conformation per-
missive for recruitment by activated Ras (17, 18). Disruption of
the Rafchaperone complex in vivo reduces the half-life of Raf
and abrogates Ras-dependent membrane recruitment (19, 20).
Raf also binds to dimerized 14–3–3 at two phosphorylated
serine residues, Ser-259 and Ser-621 (21). 14–3–3 also binds to
the Raf CRD (22), an interaction that serves to stabilize the
Raf14–3–3 complex (23). 14–3–3 binding to cytosolic Raf main-
tains Raf in an inactive conformation permissive for Ras re-
cruitment. Recruitment of Raf to the plasma membrane desta-
bilizes the interaction of 14–3–3 with the N terminus, which
allows phosphatases PP1 and PP2A to dephosphorylate Ser-
259 thus removing 14–3–3 and allowing full Raf activation
(24–27).
In mammals there are three Raf isoforms: A-Raf, B-Raf, and
Raf-1 (C-Raf). Transgenic experiments indicate that the differ-
ent Raf isoforms are non-redundant (28–33). A-Raf knockout
mice are viable but suffer intestinal and/or neurological defects
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depending on genetic background (30). B-Raf knockout mice
have defects in neuroepithelial differentiation and the mainte-
nance of endothelial cell viability and die in utero at 10–13
days post coitum due to vascular hemorrhage (31). Raf-1 knock-
out mice are anemic and die in utero or shortly after birth, with
vascular defects in the yolk sac and placenta as well as an
increase in the number of apoptotic cells throughout the em-
bryo (28, 29, 32). Intriguingly, Raf-1 Y340F/Y341F “knockin”
mice, which express the kinase-inactive RafFF mutant in place
of wild-type Raf-1, survive to adulthood with no detectable
phenotype (28). One conclusion from this study is that Raf-1
kinase function may not be required for normal mouse devel-
opment. Instead, Raf-1 could play an anti-apoptotic role during
development via a mechanism that is independent of its kinase
function, perhaps by an interaction with the pro-apoptotic,
stress activated protein kinase apoptosis signal-regulating ki-
nase 1 (34).
Investigation as to whether Raf-1 kinase activity is critical
for Raf-1 biological function is hampered in mammalian sys-
tems due to the overlapping activities of different Raf isoforms
(33). Invertebrates have only a single Raf isoform (D-Raf in
Drosophila and LIN-45 in C. elegans). In C. elegans, signaling
pathways that involve Raf are used multiple times during
development to control a variety of cell fate decisions (2). These
signaling pathways have been characterized most extensively
during the formation of the hermaphrodite vulva, a specialized
epithelial structure used for egg laying (35). A mutation that
reduces the activity of a gene in the Raf signaling pathway
generates a vulvaless (Vul) phenotype. By contrast, a mutation
that results in constitutive activity of one of these genes results
in a multivulva (Muv) phenotype. Thus, vulva formation serves
as an easily visualized readout of the activity of the Ras/Raf/
MEK/ERK-signaling pathway. This signaling pathway regu-
lates additional cell fate decisions including differentiation of
the excretory cell, which is necessary for larval viability, and
progression of germ cells through pachytene stage, which is
necessary for fertility (36, 37). As there is only a single Raf
isoform, genetic analysis in C. elegans is ideally suited to ex-
amine the functional significance of Raf within a physiological
context.
To characterize the function of the Raf gene, we used random
chemical mutagenesis and genetic screens for worms with de-
velopmental defects to identify a collection of lin-45 raf alleles
(38). The molecular lesions in these alleles were identified, and
the mutations were classified based on phenotypic severity;
they ranged from weak loss-of-function mutations that cause
mild defects to strong or complete loss-of-function mutations
that cause severe phenotypes. Six of the alleles contain mis-
sense mutations that result in substitution of a single amino
acid. To understand the biochemical defects caused by these
mutations, we engineered them into homologous residues of
vertebrate Raf-1 and characterized the biochemical properties
of the mutant proteins in vertebrate cells. These assays in-
cluded measurements of basal kinase activity, Ras-stimulated
kinase activity, membrane recruitment, and binding to 14–
3–3, Hsp90, Cdc37, and MEK. Our analysis identifies function-
ally significant residues in the Ras-binding domain, protein
kinase domain as well as MEK and 14–3–3-binding domains
and demonstrates the necessity of these residues and domains
for Raf activity in an animal. An interesting observation that
mirrors the Raf-1 knockout mice studies recently published is
that in vitro Raf kinase activity does not necessarily correlate
to the in vivo function of the Raf protein. The significance of
this apparently paradoxical observation is discussed.
MATERIALS AND METHODS
Plasmids and Mutagenesis—Raf mutant constructs were generated
using the QuikChange site-directed mutagenesis kit (Stratagene) using
a human Raf-1 or B-Raf clone tagged with a FLAG or myc epitope. All
constructs were sequenced prior to use. EXV-K-RasG12V, EXV-FLAG-
Raf, EXV-FLAG-RafDD, and EXV-FLAG-RafCAAX have all been pre-
viously described (39). Raf-GFP was constructed by subcloning the
Raf-1 cDNA into pEGFP-N3 (Clontech).
Cell Culture and Antibodies—COS cells and baby hamster kidney
cells (BHK) were grown and maintained in HEPES-buffered Dulbecco’s
modified Eagle’s medium containing 10% donor calf serum as described
previously (39). Mouse monoclonal antibodies, anti-Raf-1, Hsp90, and
Cdc37, were obtained from Transduction Laboratories, and anti-FLAG
from Eastman Kodak Co. Polyclonal anti-14–3–3 antibody was ob-
tained from Santa Cruz Biotechnology, Inc. Anti-Ras rat monoclonals
(Y13–259 and Y13–238) were made from hybridomas acquired from the
American Type Culture Collection. Polyclonal GFP antibody was ob-
tained from I.A. Prior (University of Queensland) and monoclonal GFP
antibody from Roche Applied Science. Phospho-MEK polyclonal and
phospho-ERK monoclonal antibodies were purchased from New Eng-
land Biolabs. Polyclonal MEK-1/2 (New England Biolabs) and ERK-1
polyclonal (Santa Cruz) were used as input control antibodies where
indicated.
Cell Transfection and Immunofluorescence—COS cells were electro-
porated as described previously (40). After 54 h cells were switched to
serum-free medium and incubated for a further 18 h before harvesting.
BHK cells were seeded onto coverslips for immunofluorescence or 10-cm
dishes for biochemical assays, and transfected using LipofectAMINE
(Invitrogen) according to the manufacturer’s instructions. Cells on
10-cm dishes were maintained in serum-free Dulbecco’s modified Ea-
gle’s medium for 16 h after lipofection before being harvested. Cells
were washed and scraped on ice into 0.5 ml of buffer A (10 mM Tris-HCl,
pH7.5, 25 mM NaF, 5 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 100
M NaVO4). After 10 min on ice, cells were passed 25 through a
23-gauge needle and the nuclei removed by low speed centrifugation.
Post-nuclear supernatants were spun at 100,000  g. The supernatant
(S100) was removed, and the sedimented fraction (P100) was rinsed and
sonicated for 5 min in 100 l of ice-cold buffer A. The S100 fraction and
resuspended P100 fractions were snap-frozen and stored at 70 °C in
aliquots after measuring protein content by the Bradford reaction. Cells
on coverslips were fixed in 4% paraformaldehyde 24 h after lipofection.
The coverslips were washed for 10 min in phosphate-buffered saline,
permeabilized with 0.2% Triton X-100 in phosphate-buffered saline,
and blocked in 3% bovine serum albumin in phosphate-buffered sa-
line. The primary antibody Y13–238 (Ras) was diluted in blocking buffer
at a 1:2 to 1:30 dilution and the secondary antibody, anti-rat CY-3, used at
1:300 dilution. Raf-GFP was visualized by direct fluorescence.
Western Blotting—Expression and subcellular localization of ectopi-
cally expressed proteins were determined by immunoblotting. Cellular
fractions, normalized for protein content, were resolved on SDS-PAGE
gels and transferred to polyvinylidene difluoride membranes using
semi-dry transfer. The membranes were probed with anti-Raf-1,
Y13–259 for Ras, or anti-14–3–3, anti-Hsp90, anti-CDC37, or anti-GFP
monoclonal and polyclonal antibodies as appropriate, then developed
using horseradish peroxidase-conjugated secondary antibodies and en-
hanced chemiluminescence. Where indicated immunoblots were quan-
tified by phosphorimaging (Bio-Rad).
Raf Kinase Assays—P100 aliquots of transfected cells were normal-
ized for protein content and assayed for Raf activity using a two-stage
coupled MEK/ERK assay with phosphorylation of myelin basic protein
as readout (39). For assays of cytosolic Raf proteins, S100 fractions were
normalized for Raf content and Raf proteins immunoprecipitated with
M2 anti-FLAG monoclonal or anti-GFP polyclonal antibodies as previ-
ously described (23). Immunoprecipitates were then assayed for Raf
activity as above. After the kinase assays, immunoprecipitates were
taken up in SDS-PAGE sample buffer, resolved by SDS-PAGE, and
immunoblotted.
RESULTS
Identification and Molecular Characterization of lin-45 raf
Alleles—Alleles of lin-45 raf were identified by conducting ge-
netic screens for C. elegans hermaphrodites with defective vul-
val development or sterility. To investigate how these muta-
tions affect the activity of lin-45 and the role of lin-45 during
development, the phenotypes of these mutants were character-
ized extensively (38). Based on these findings, the alleles were
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arranged in a series of increasing severity that is likely to
correspond to an increasing loss of lin-45 activity; the series is
the same whether larval lethality, vulval formation, or sterility
are considered (Ref. 38 and Table I).
The Effect of lin-45 Loss-of-function Mutations on Ras Medi-
ated Raf-1 Activation—To elucidate the biochemical basis of
the inactivating mutations in lin-45, we initially generated the
loss-of-function point mutations in lin-45. However, when ex-
pressed in mammalian cell lines the LIN-45 protein was cata-
lytically inactive. We therefore turned to the well characterized
model system of Ras-dependent Raf-1 activation in COS cells.
K-Ras was used for these experiments because this mamma-
lian Ras isoform most closely resembles C. elegans let-60 ras.
Amino acid substitutions were introduced into FLAG-Raf
(Raf-1 with an N-terminal FLAG epitope tag) at residues cor-
responding to the lin-45 loss-of-function point mutations iden-
tified in the genetic screens (Table I and Fig. 1). Briefly, the
lin-45 mutations P92S, R108W, R118W, S645N, I726F, and
S754F were introduced at the homologous Raf-1 residues P63S,
H79W, R89W, S508N, V589F, and S619F, respectively. Wild-
type and mutated FLAG-Raf-1 constructs were co-expressed
with constitutively active RasG12V in COS cells. Membrane
fractions of these cells were normalized for Raf-1 content, and
Raf-1 kinase activity was measured in a coupled MEK/ERK
assay. Fig. 2 shows that all of the lin-45 point mutations,
except H79W, profoundly abrogated K-Ras-dependent Raf-1
activation. Raf-1 mutants resistant to RasG12V activation may
be deficient in membrane recruitment or refractory to later
membrane activation events. To examine Ras-dependent
plasma membrane recruitment, the lin-45 point mutations
were introduced into Raf-GFP (Raf-1 with a C-terminal GFP
epitope tag). BHK cells were then co-transfected with the Raf-
GFP constructs and RasG12V. Plasma membrane recruitment
was assessed using confocal microscopy. Fig. 3 shows that
Raf-GFP plasma membrane recruitment was abrogated by the
two RBD point mutations P63S and R89W but was unaffected
by the H79W substitution. None of the mutations outside of the
Raf RBD compromised Raf-GFP membrane recruitment.
Effect of lin-45 Loss-of-function Mutations on Raf-1 Basal
Kinase Activity and Associated Proteins—We next examined
the effect of the lin-45 point mutations on Raf-1 basal kinase
activity and interaction with known associated proteins.
FLAG-Raf and Raf-GFP constructs containing lin-45 point
mutations were expressed equivalently in COS cells and
anti-FLAG or anti-GFP immunoprecipitates prepared from the
cytosolic S100 fraction. Basal Raf kinase activity in immuno-
precipitates normalized for Raf-1 protein was measured in a
coupled MEK/ERK assay. The results in Fig. 4 show that point
mutations within the Raf RBD, P63S, H79W, and R89W, had
no effect on Raf-1 basal kinase activity. In contrast, point
mutations within the Raf kinase domain, S508N and V589F,
and a point mutation directly adjacent to the COOH-terminal
14–3–3 binding motif (S619F) all markedly reduced basal
kinase activity. Immunoprecipitates were then blotted for
14–3–3, Cdc37, and Hsp90, which are important co-factors for
Raf-1 activation. (FLAG immunoprecipitates could not be
blotted for Cdc37, or GFP immunoprecipitates for 14–3–3, due
to secondary antibody species cross-reactivity.) The mutations
P63S, V589F, and S619F severely reduced the association of
14–3–3 with Raf-1, but no mutation had any significant effect
on Hsp90 or Cdc37 interactions. Thus reduced 14–3–3 associ-
ation has a minimal effect on Cdc37 or Hsp90 interactions with
Raf-1.
Basal Raf-1 kinase activity could be reduced because of in-
creased interaction between the N-terminal regulatory and
catalytic domains, or structural disruption of the Raf-1 kinase
domain. Replacement of tyrosines 340 and 341 with aspartic
acid partially relieves the negative regulation of Raf-1 by the
regulatory N terminus (41), allowing us to discriminate be-
tween these possibilities. We therefore introduced the lin-45
mutations into FLAG-Raf Y340D/Y341D (RafDD), and meas-
ured the Raf-1 kinase activity of anti-FLAG immunoprecipi-
tates normalized for Raf-1. Fig. 5 shows that the kinase activity
of the Y340D/Y341D substituted RBD mutant proteins was the
same as RafDD. In contrast, the kinase activity of the S508N
mutant was only partially up-regulated, whereas the V589F
and S619F Raf mutants displayed no up-regulation of kinase
activity in the presence of the activating substitutions. The
lin-45 point mutations had identical effects on 14–3–3 interac-
tions with RafDD as with wild-type Raf-1 (Fig. 5).
Effect of lin-45 Loss-of-function Mutations on the Activity of
Membrane-targeted Raf-1—The full activation of Raf-1 follow-
ing recruitment to the plasma membrane involves interactions
with lipids, kinases, and phosphatases. Ras-independent acti-
vation of Raf can occur if Raf is targeted to the plasma mem-
brane using the C-terminal K-Ras localization signals (Raf-
CAAX) (12). Lin-45 point mutations were therefore introduced
into RafCAAX to determine whether any could be rescued by
constitutive plasma membrane localization. Membrane frac-
tions of COS1 cells expressing the constructs were normalized
TABLE I
lin-45 mutations cause larval lethality, sterility, and abnormal vulva formation
Twelve lin-45 alleles were identified using random chemical mutagenesis and screens for abnormal vulval development or sterility. This
collection includes six different missense mutations that result in single amino acid substitution: three alleles contain nonsense mutations
(described in Ref. 38). lin-45 mutations can be arranged in an allelic series that corresponds to an increasingly severe loss of LIN-45 activity. The
oz201 mutation appears to cause a complete loss of LIN-45 activity. Because oz201 causes completely penetrant sterility, oz201 homozygous
mutants were derived from oz201/ hermaphrodites. The other mutant strains are fertile, and homozygous mutants were derived from
homozygous mutant hermaphrodites.
Genotype LIN-45 mutation Raf-1 mutation Larval lethala Abnormal vulvab Sterileb Classificationc
% % %
Wild-type 0 0 0
n1925 R108W H79W 1 1 0 W
n1924 I726F V589F 5 0 1 W
n2520 S754F S619F 0 0 0 W
n2018 P92S P63S 76 24 1 I
n2506 R118W R89W 86 93 3 I
oz201 S645N S508N 55 100 100 S
a The percentage of hatched eggs judged to be homozygous mutants that generated dead larvae; most dead larvae displayed rigid, rod-like
morphology.
b The percentage of all adult hermaphrodites judged to be homozygous mutants that displayed a severe egg-laying defect, no discernable vulva,
or a protruding vulva (abnormal vulva) or that generated no larval progeny (sterile). A more detailed genetic analysis of the mutants is displayed
in Hsu et al. (38).
c W, weak; I, intermediate; and S, strong.
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for Raf content, and Raf-1 activity was measured in a coupled
MEK/ERK assay. Membrane targeting fully activated the
P63S, H79W, and R89W mutants, partially activated the
FIG. 2. Ras-dependent activation of lin-45 loss-of-function mu-
tations. COS cells transfected with activated RasG12V and Raf-1 con-
structs indicated were fractionated and crude membrane (P100) frac-
tions were immunoblotted for Ras and Raf-1 (lower panel). P100
fractions from each transfection were normalized for Raf-1 content and
assayed for Raf-1 kinase activity using a coupled MEK/ERK assay
(upper panel). The results show mean Raf specific activity from a single
transfection assayed in duplicate. Similar results were obtained in
three independent COS cell transfections.
FIG. 3. Ras-dependent plasma membrane recruitment of lin-45
loss-of-function mutations. BHK cells were co-transfected with acti-
vated RasG12V and Raf-GFP containing lin-45 mutations. Raf-GFP
proteins were detected by direct fluorescence. Representative cells are
shown.
FIG. 1. Insertions of lin-45 loss-of-function point mutations into mammalian Raf-1. Amino acid substitutions were introduced into
FLAG-Raf (Raf-1 with an N-terminal FLAG epitope tag) and Raf-GFP (Raf-1 cloned onto the N terminus of GFP). Based on mutations in lin-45
that cause the substitutions P92S, R108W, R118W, S654N, I726F, and S755F, we introduced mutations that change the homologous Raf-1 residues
P63S, H79W, R89W, S508N, V589F, and S619, respectively.
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S508N mutant, and failed to activate the V589F and S619F
mutants (Fig. 6A). These results, in combination with the data
in Fig. 5, suggest that the kinase function of S508N is partially
compromised, and the kinase function of the V589F and S619F
mutants is highly compromised. This is surprising given that
the equivalent mutations to V589F and S619F in C. elegans
lin-45 only caused weak phenotypes. The C. elegans genetic
analysis nevertheless indicates that a functional kinase do-
main is necessary for biological function because a nonsense
mutation that encodes a LIN-45 protein lacking a kinase do-
main displayed the strongest phenotype (38).
Although the well characterized coupled Raf/MEK/ERK as-
say gives an accurate estimate of Raf kinase activity, we won-
dered whether it accurately reflected the ability of plasma
membrane-localized Raf to activate MEK in intact cells. To test
this hypothesis, we transfected kinase inactive RafCAAX con-
structs with the mutations S508N, V589F, and S619F and
kinase inactive RafCAAX containing the mutations Y304F/
Y341F (RafCAAX-FF) into BHK cells. BHK cells were used for
these experiments as they are transfected with greater than
80% efficiency, thus greatly reducing background derived from
non-transfected cells. As a control we expressed a “true” ki-
nase-inactive RafCAAX (RafCAAX-KD) that has a K375M sub-
stitution in the ATP binding site and is therefore unable to
catalyze phosphotransfer reactions (5). MEK phosphorylation
was used as the readout for in vivo Raf-1 kinase activity.
Transfected cells were fractionated into membrane (P100) and
cytosolic (S100) fractions then immunoblotted for phospho-
MEK (Fig. 6B). Strikingly, only RafCAAX-KD was unable to
phosphorylate and activate MEK. RafCAAX-FF, RafCAAX-
V589F, and RafCAAX-S619F, which had no measurable Raf
kinase activity in vitro, and RafCAAX-S508N, which had
greatly reduced kinase activity in vitro, were able to activate
MEK to comparable levels as the wild-type RafCAAX in vivo.
Ser-508 in Raf-1 and Ser-615 in B-Raf Regulate Raf-MEK
Interactions—Although Raf-S508N displayed reduced kinase
activity in the constitutive activated Raf-1 background, it was
fully competent for MEK activation in vivo. Nevertheless, this
FIG. 4. Effect of lin-45 loss-of-function mutations on Raf-1 basal kinase activity and associated proteins. COS cells transfected with
Raf-1 and Raf-GFP constructs containing lin-45 loss-of-function mutations were fractionated, and the S100 fraction normalized for Raf-1 content.
Transfected Raf-1 proteins were immunoprecipitated from the S100 (S100 IP) fraction using anti-FLAG (panel A) and anti-GFP (panel B)
antibodies, respectively. Anti-FLAG immunoprecipitates were blotted for Raf-1 and 14–3–3 (A, lower panels) and anti-GFP immunoprecipitates
blotted for Raf-1, Cdc37, and Hsp90 (B, lower panels). The basal kinase activity of Raf-1 was determined by measuring Raf kinase activity
associated with the immunoprecipitates using a coupled MEK/ERK kinase assay performed in triplicate. Typical kinase assays are shown in the
lower panels of A and B and the mean of three independent assays displayed graphically in the upper panels. Similar results were obtained in three
independent experiments.
FIG. 5. Effect of lin-45 loss-of-function mutations on constitu-
tively activated Raf-1. Replacement of Raf-1 tyrosines 340 and 341
with aspartic acid (RafDD) activates Raf-1 independently of Ras. lin-45
mutations were introduced into FLAG-RafDD, and the constructs were
expressed in COS cells. Mutant RafDD proteins were immunoprecipi-
tated using anti-FLAG antibodies from the S100 fraction (S100 IP).
Immunoprecipitates were assayed for Raf kinase activity in a coupled
MEK/ERK kinase assay performed in duplicate (shown as a graph in
upper panel with a representative kinase assay gel shown in lower
panel) then blotted for Raf-1 and 14–3–3 (lower panels). Similar results
were obtained in three independent transfections.
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mutant displayed the strongest phenotype of all the lin-45
missense mutations (Table I and Ref. 38). Serine 508 lies
within kinase subdomain VIII and forms part of the activation
loop of Raf. Phosphorylation on Raf-1 residues Thr-491 and
Ser-494 within the activation loop up-regulates Raf kinase
activity and is a common mechanism used to control Raf bio-
logical function in both C. elegans and mammals (42). Phospho-
rylation within the kinase activation loop can provide catalytic
activation through modulation of substrate binding and/or
phosphoryl transfer (43). As we have shown that Raf-1 with a
S508N substitution can still catalyze the phosphotransfer re-
action in vitro and in vivo, we examined whether this residue
modulates substrate binding. Serine is also a potential phos-
phorylation site, and many protein kinases have a serine or
threonine residue at the equivalent residue within the activa-
tion loop (44). We therefore substituted serine 508 with aspar-
tic acid in activated RafDD to mimic the negative charge im-
parted by phosphorylation and examined the effect of this
substitution on the ability of Raf-1 to bind to MEK in vivo and
activate MEK in vitro. GFP-tagged RafDD, RafDD-S508N, and
RafDD-S508D constructs were expressed in COS cells and the
Raf-1 immunoprecipitated with GFP antibody. The immuno-
precipitates were divided into two identical aliquots and either
assayed for Raf kinase activity or probed for Raf and MEK1/2.
RafDD was catalytically active and co-precipitated MEK. In
contrast, RafDD-S508N displayed compromised catalytic activ-
ity, which correlated with a dramatic reduction in MEK bind-
ing. The RafDD-S508D protein displayed a severe defect in
catalytic activity and did not co-precipitate any detectable
MEK protein (Fig. 7A). Thus, the decrease in catalytic activity
of the two mutant proteins correlated with a decrease in sub-
strate affinity. To confirm that this residue has a conserved
function throughout the Raf kinase family, the equivalent res-
idue was mutated in myc-tagged B-Raf to generate the mutant
proteins B-Raf-S615N and B-Raf-S615D. The wild-type and
mutant B-Raf proteins were expressed in COS cells, immuno-
precipitated with myc antibody, and analyzed for catalytic ac-
tivity and substrate binding exactly as performed for RafDD
(Fig. 7A). The B-Raf results were in exact agreement with those
obtained for constitutively active Raf-1, showing that decreas-
ing catalytic activity correlated with decreasing substrate bind-
ing. These findings strongly support the hypothesis that this
residue has a general function in all Raf proteins.
As mutant Raf proteins with compromised catalytic activi-
ties can still activate MEK in intact cells, we investigated
whether a S508D substitution was sufficient to inactivate Raf
in vivo. To test this, we expressed constitutively active Raf-
CAAX, kinase inactive RafCAAX-KD, and the mutant proteins
RafCAAX-S508N and RafCAAX-S508D in BHK cells and as-
sessed the ability of the mutant proteins to phosphorylate MEK
in vivo. Strikingly, RafCAAX-S508D was profoundly compro-
mised in its ability to phosphorylate MEK in vivo compared
with both RafCAAX and RafCAAX-S508N (Fig. 7B). This result
shows that a negative charge on Ser-508 efficiently down-
regulates Raf catalytic activity in living cells.
The Ser-508 Residue Is Critical for Proper Receptor-mediated
Raf-1 Activation—Raf proteins require phosphorylation of two
conserved sites within the activation loop for full activation
(42). We have shown that mutation of the C-terminal serine of
the activation loop (Raf-1-S508N, B-Raf-S615N) reduced both
catalytic activity and substrate binding. Mutation of this resi-
due may reduce phosphorylation of the activating residues
within the activation loop in response to growth factors, or
perturb the activation loop such that it cannot form a stable
structure after phosphorylation has occurred. One prediction of
this hypothesis is that Raf-1 with a S508N substitution will
display aberrant activation kinetics in response to growth fac-
tor stimulation. To test this prediction, GFP-tagged wild-type
Raf-1 and Raf-S508N were expressed in cells arrested at G0 by
serum starvation and then subsequently stimulated by EGF
addition. These cells were harvested at time points up to 10
min post-EGF treatment to assess the profile of Raf-1 activa-
tion. Wild-type Raf-1 displayed two distinct phases of activa-
tion and deactivation within this time frame (Fig. 8). In strik-
ing contrast, Raf-S508N, although competent for the first
phase of activation at 1 min, was subsequently refractory to the
second phase of EGF-receptor activation at 10 min post-EGF
(Fig. 8). This result demonstrates that in addition to low kinase
activity, the Raf-S508N mutant also possesses an aberrant
activation profile in response to growth factor mediated
activation.
DISCUSSION
We previously identified a series of point mutations within
C. elegans lin-45 raf that generated loss-of-function phenotypes
and which we scored as weak, intermediate, or strong based on
phenotypic severity (Table I). The mutant lin-45 raf alleles
were assayed in a physiological setting, and for mutations that
could be maintained as homozygotes, the mutant protein com-
FIG. 6. Effect of lin-45 mutations on membrane targeted Raf-
CAAX. Targeting Raf-1 to the plasma membrane activates Raf-1 inde-
pendently of Ras. COS cells expressing plasma membrane targeted
RafCAAX constructs containing lin-45 mutations were fractionated into
P100 and S100 fractions. P100 fractions normalized for Raf-1 content
were assayed in duplicate for Raf-1 kinase activity in a coupled MEK/
ERK assay. Identical aliquots of the P100 fractions were then immu-
noblotted for Raf-1 (panel A). Similar results were obtained in three
independent transfections. BHK cells transfected with membrane tar-
geted RafCAAX constructs were serum-starved and fractionated. 20 g
of the P100 fractions were immunoblotted for Raf-1 and equivalent
portions of the S100 fractions immunoblotted for phospho-MEK
(pMEK) and MEK1/2 as input control (panel B).
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pletely replaced wild-type LIN-45. This genetic analysis pro-
vided strong evidence for the functional significance of partic-
ular residues and domains, but it did not reveal the biochemical
basis underlying the phenotype caused by the mutant proteins.
To understand the biochemical defects caused by these muta-
tions, we engineered them into the equivalent residues of Raf-1
and assayed the mutant proteins for defects in biological and
biochemical functions including subcellular localization, kinase
activity, and binding to defined protein partners. This combi-
nation of approaches is powerful because if a mutation causes
a functional deficit and a biochemical defect, this correlation
indicates that the biochemical activity is functionally
significant.
Three mutations were identified that affect the minimal Raf
RBD. The substitutions P92S(lin-45)/P63S(Raf-1) and R118W
(lin-45)/R89W(Raf-1) caused an intermediate loss-of-function
in C. elegans. Both proteins were refractory to recruitment and
activation by Ras-GTP. However, both proteins displayed nor-
mal basal kinase activity and could be rescued by constitutive
plasma membrane targeting and activating point mutations.
These findings indicate that these residues are required for the
recruitment of Raf from the cytosol to plasma membrane but do
not effect subsequent activation steps. The crystal structure of
the Raf-1 RBD in complex with Rap has been solved (45), and
Arg-89 of the Raf-1 RBD shown to directly stabilize the inter-
action through polar interactions and water-mediated contact.
FIG. 7. The Raf-1-S508/B-Raf-S615
residue mediates substrate binding.
A, COS cells expressing GFP alone or
GFP-tagged constitutively activated
Raf-1 constructs (left panel), empty vector
or B-Raf constructs (right panel) were ly-
sed in buffer B and Raf-1 immunoprecipi-
tated from the cleared lysate using rabbit
anti-GFP attached to protein-A agarose
(GFP-IP) and B-Raf immunoprecipitated
using anti-myc attached to protein-G aga-
rose (myc-IP). After extensive washing
the beads were resuspended in sample
buffer and the immunoprecipitated pro-
teins resolved by SDS-PAGE, then immu-
noblotted for Raf-1 or B-Raf and MEK1/2.
20 g of the cleared lysate was immuno-
blotted for MEK1 as an input control. B,
BHK cells expressing membrane targeted
Raf-CAAX constructs were serum-starved
then fractionated into P100 and S100
fractions. 20 g of the P100 fractions were
immunoblotted for Raf-1 and 20 g of the
S100 for pMEK and MEK1/2 as input con-
trol. Cells transfected with vector alone
(mock) were included as a negative
control.
FIG. 8. The Raf-S508 residue is critical for proper growth factor-mediated Raf-1 activation. COS cells transfected either with Raf-GFP
or RafS508N-GFP, respectively, were pooled after transfection and then divided into 6 identical aliquots to ensure equivalent expression across the
EGF time course. At 48 h post-transfection the cells were serum-starved for 18 h then stimulated with 50 nM EGF. Cells were harvested up to 10
min post-EGF addition and fractionated into P100 and S100 fractions. The P100 fractions were then solubilized in buffer A containing 1% Triton
X-100, and Raf-GFP immunoprecipitated from the cleared P100 supernatant. After extensive washing, immunoprecipitated Raf-1 was assayed for
kinase activity using the in vitro coupled assay, and the immunoprecipitates were immunoblotted for Raf-1. A comparison of the relative kinase
activity of the Raf-1 wild-type and Raf-S508N at 1-min post-EGF addition is shown as an inset.
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Mutational analyses have also shown that Arg-89 is critical for
the interaction between the Raf-1 RBD and the Ras effector
domain (15, 16). Our results are in complete agreement with
these studies and confirm a physiological role for the Ras-GTP/
Raf interaction.
In contrast, the P92S(lin-45)/P63S(Raf-1) residue is not di-
rectly involved in binding the Ras-GTP effector domain.
Rather, this conserved residue lies between two  sheets (B1
and B2) in the Raf-1 RBD (45). It is likely that this residue is
folded in a hydrophobic region of the protein and has a role in
maintaining the appropriate structure of the Raf RBD. In
agreement with this prediction the point mutation P63S com-
pletely abrogated Ras-GTP mediated recruitment. The P63S
mutant also displayed reduced 14–3–3 binding relative to wild-
type Raf-1. We have previously shown that the Raf-1 CRD
stabilizes the interaction between Raf-1 and 14–3–3 (23). It is
possible that the P63S substitution destabilizes not only the
Raf-1 RBD structure but also the adjacent CRD and hence
destabilizes the Raf-1/14–3–3 complex. Although these RBD
mutants were unable to bind Ras-GTP, they displayed only an
intermediate phenotypic strength in the C. elegans genetic
screens (38). This indicates that in addition to direct contact
between the Raf RBD and Ras effector domain, secondary
mechanisms must exist that couple Ras-GTP to Raf that can
partially compensate for a non-functional Raf RBD in vivo.
Sur-8 is a scaffold protein found in both C. elegans and mam-
mals (46, 47) that enhances ERK1/2 signaling by forming a
complex with Ras and Raf (48). In addition, agonist-dependent
translocation of Raf-1 to the plasma membrane is mediated
primarily through a Ras-independent association with phos-
phatidic acid (Ref. 49 and references therein). Thus there are at
least two mechanisms that might facilitate Raf membrane re-
cruitment independently of the Raf RBD. Our data strengthens
the hypothesis that these secondary mechanisms for coupling
Ras-GTP to Raf are functionally important in the living animal.
The substitution R108W (lin-45)/H79W (Raf-1) caused a
weak loss of function in C. elegans. Consistent with this weak
phenotype, the mutant protein was indistinguishable from
wild-type Raf-1 in our assays. It is likely that the substitution
causes a biochemical defect that is too subtle to be detected
using ectopic expression of the mutant protein. However, we
cannot exclude the possibility that this residue may have a
function in LIN-45 that is not conserved in vertebrate Raf-1, or
that the residue mediates a biochemical function that was not
assayed.
Two mutations were identified that affect the protein kinase
domain: S645N(lin-45)/S508N(Raf-1) and I726F(lin-45)/
V589F(Raf-1). A point mutation within the C-terminal 14–3–3
binding site was also identified S754F(lin-45)/S619F(Raf-1).
All three of these mutations had a profound effect on the kinase
activity of the Raf-1 protein as judged by the in vitro Raf-1
kinase assay. Raf S508N was recruited to the plasma mem-
brane by activated Ras, but was poorly activated. However, Raf
S508N was partially activated when placed in constitutively
activated Raf-1 (RafDD) or membrane-targeted Raf-1 (Raf-
CAAX). The V589F and S619F Raf-1 mutant proteins were
recruited normally by RasG12V but not activated. Because
neither of these mutants kinase activity was up-regulated by
Y340D/Y341D substitutions or membrane targeting these re-
sults show that the I726(lin-45)/V589(Raf-1) and S754(lin-45)/
S619(Raf-1) residues are critical for the kinase function of Raf
proteins. Both of these mutant proteins were also defective for
14–3–3 binding. Thorson et al. (50) showed that autophospho-
rylation of Ser-621 is essential for maintaining the interaction
of 14–3–3 with the isolated Raf kinase domain. They also
described mutations at Ser-619 that prevented 14–3–3 associ-
ation and destroyed kinase activity of the isolated Raf-1 cata-
lytic domain. Our results confirm that this observation also
holds for the full-length Raf-1 molecule.
A critical question that arises from the genetic and biochem-
ical analysis is to what extent Raf biological function is deter-
mined by its kinase activity toward MEK. For example, Raf-1
V589F and S619F mutations completely abrogate Raf-1 kinase
activity as measured by a standard in vitro coupled assay, yet
the corresponding mutations in lin-45 cause weak loss-of-func-
tion phenotypes. In contrast the S508N mutant, which displays
a reduced but still functional kinase activity in vitro, exhibits
the strongest phenotype of all the mutants with a single amino
acid substitution. The C. elegans genetic analysis clearly cor-
relates to kinase activity of the LIN-45 protein, as the alleles
dx19 and n2510, which encode proteins that lack the kinase
domain, displayed the strongest phenotypes (38). These results
are reminiscent of recent studies examining the function of
Raf-1 in mouse development. The Raf-1/ null mouse is non-
viable with the embryo showing defects in vascularization and
placental development as well as increased apoptosis in many
tissues (28, 29, 32). In contrast, knock-in mice expressing mu-
tant Raf-1 Y340F/Y341F in place of endogenous Raf-1 survive
to adulthood, are fertile and have an apparently normal phe-
notype (28). Raf-1 requires phosphorylation of Tyr-340 and/or
Tyr-341 for full activation (41, 51). Substitution of these resi-
dues to phenylalanine blocks activation of Raf-1 by oncogenic
Ras and Src and by constitutive membrane targeting (39).
However, mouse embryonic fibroblasts derived from Raf-
Y340F/Y341F (RafFF) embryonic tissue showed no increase in
programmed cell death relative to wild-type cells and displayed
normal proliferation and ERK activation (28). One possible
conclusion of the RafFF transgenic study is that the critical
biological function of Raf-1 is not dependent on its ability to
phosphorylate and activate MEK. In support of this hypothesis
an anti-apoptotic, kinase-independent function for Raf-1 has
been demonstrated (34). Raf-1 interacts with the pro-apoptotic,
stress-activated protein kinase apoptosis signal-regulating ki-
nase 1 in vitro and in vivo. This interaction allows Raf-1 to
inhibit apoptosis independently of the MEK-ERK pathway.
The results presented here, however, provide strong evi-
dence that kinase activity is critical for biological function of
Raf proteins in an animal. As Raf-1 is the only Raf isoform
ubiquitously expressed in mammals (52), and a large body of
evidence suggests Raf-1 kinase activity is indeed essential for
its function (reviewed in Ref. 51), caution should be applied
before dismissing Raf-1 kinase activity as redundant for its
biological function. We have demonstrated that Raf kinase
activity as measured by sensitive in vitro kinase assays does
not reflect in vivo kinase activity of Raf proteins. In the defin-
itive experiment, we show that membrane targeted RafCAAX-
FF, RafCAAX-V589F and RafCAAX-S619F, all of which are
kinase-inactive in vitro, efficiently phosphorylate and activate
MEK in vivo. However, membrane targeted RafCAAX-KD,
which cannot bind ATP to perform the phosphotransfer reac-
tion and is truly kinase dead, cannot activate MEK in vivo. One
possible explanation for the difference between in vitro and in
vivo kinase activity is the presence in vivo of potential acces-
sory molecules such as adaptors and scaffolds that facilitate the
assembly of enzyme-substrate complexes. Scaffold complexes
for MAPK pathways have been well characterized in yeast
(reviewed in Ref. 53) and function to increase both the effi-
ciency and specificity of the signaling cascade (54). Several
scaffold-like proteins have been identified for the Raf-MAPK
cascade (reviewed in Refs. 55–57). Whatever underlying mech-
anisms are involved, the discrepancy between in vitro and in
vivo Raf-1 kinase activity accounts for the apparently paradox-
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ical result of the kinase inactive mutations V589F (n1924) and
S619F (n2520) retaining biological function in the animal
model. These results also provide an alternative explanation
for the ability of RafFF to substitute for wild-type Raf-1 in
mouse genetic studies without needing to revoke the well es-
tablished kinase function of the Raf-1 protein.
In contrast, the S645N(lin-45)/S508N(Raf-1) mutant dis-
played kinase activity in vitro, was fully competent for activa-
tion of MEK when targeted to the plasma membrane, yet had
the strongest phenotype of all the substitution mutants (Table
I and Ref. 38). When this residue was mutated to aspartic acid
(Raf-S508D), the mutant protein was severely compromised for
in vivo MEK activation compared with wild-type Raf and all
the kinase defective Raf mutants analyzed (compare Figs. 6B
and 7B). This raises the intriguing possibility that phosphoryl-
ation of Ser-508 could negatively regulate Raf kinase activity in
vivo. Although Ser-508 is not strictly conserved among all
kinases, the majority of protein kinases contain either a serine
or threonine residue at the equivalent position (44). Ser-508
lies within the Raf activation loop and appears to be critical for
the proper function of this domain. Mutation of this residue in
Raf-1, or the equivalent residue in B-Raf, also greatly reduced
Raf-MEK binding (Fig. 7A) and perturbed Raf activation kinet-
ics (Fig. 8). The simplest interpretation of these combined data
is that Ser-508 is critical for the structural integrity of the
activation loop, and that mutation to asparagine disorders the
activation loop so that it occupies the active site, thereby in-
hibiting substrate binding. The loss of structural integrity
caused by the asparagine substitution may also inhibit phos-
phorylation of the Raf activation loop on the critical activating
residues, or prevent the phosphorylated activation loop from
folding into the well ordered structure necessary to generate
the catalytically active conformation. Both mechanisms are
compatible with the observed aberrant activation kinetics of
the mutant Raf-S508N protein in response to growth factor
stimulation. As the only activating phosphorylation sites found
in C. elegans, Raf are located within the activation loop (42),
perturbing the structure and or function of the activation loop
would be expected to severely inhibit the increase of lin-45
kinase activity in response to growth factor stimulation. We
conclude therefore that the strong phenotype displayed by the
S645N(lin-45)/S508N(Raf-1) mutant in the genetic screens re-
sults from a combination of the reduced substrate binding and
inability to respond to phosphorylation events in the activation
loop, resulting in aberrant activation kinetics in response to
growth factor stimulation.
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